甲强龙与复方磺胺甲噁唑联用对中重度缺氧艾滋病患者伴肺孢子菌肺炎的临床疗效评价
|
摘要
目的:探究甲强龙与复方磺胺甲噁唑对中重度缺氧艾滋病患者伴肺孢子菌肺炎的临床疗效及其对动脉血氧分压(PaO_2)、末梢血氧饱和度(SpO_2)的影响。方法:选取2015年1月—2018年8月间收治的中重度缺氧艾滋病患者伴肺孢子菌肺炎患者60例资料,按其治疗方法的不同将其分为对照组和观察组,每组30例;对照组患者给予复方磺胺甲噁唑治疗,观察组患者给予甲强龙与复方磺胺甲噁唑治疗,比较两组患者治疗后的总有效率、呼吸困难及肺部病变改善率差异,以及治疗不同时段后PaO_2、SpO_2水平测得值的变化情况。结果:治疗7 d后,观察组患者PaO_2、SpO_2和呼吸困难改善率优于对照组(P<0.05);而肺部病变改善率两组间经组间比较其差异无统计学意义(P>0.05);治疗21 d后肺部病变改善率优于对照组(P<0.05);观察组患者PaO_2、SpO_2和呼吸困难及肺部病变的改善率均优于对照组(P<0.05)。结论:采用甲强龙与复方磺胺甲噁唑治疗中重度缺氧艾滋病伴肺孢子菌肺炎患者的疗效较为确切,有效改善了其PaO_2、SpO_2水平和呼吸困难状况,提高了患者的生活质量。
Objective: To evaluate the clinical efficacy of methylprednisolone combined with compound sulfa-methoxazole in moderate and severe hypoxic AIDS with pneumocystis pneumonia and its influence on arterial partialoxygen pressure(PaO_2) and peripheral oxygen saturation(SpO_2). Methods: 60 cases of AIDS complicated with Pneu-mocystis jeroveci pneumonia from January 2015 to January 2018 in our hospital were selected. Based on their differenttreatment methods, they were divided into two groups: the control group(n=30 cases) and the observation group(n=30 cases). The control group was treated with compound sulfamethoxazole, and the observation group was treated withmethylprednisolone combined with sulfamethoxazole. The efficacies of two treatments were compared in total efficientrate. Results: There was no significant difference in PaO_2, SpO_2, dyspnea and pulmonary lesions between the twogroups before treatment(P>0.05). After 7 days of treatment, the PaO_2, SpO_2 and dyspnea in the observation group wereimproved compared with those in the control group(P<0.05), but there was no significant difference in lung conditionbetween the two groups(P>0.05). After 21 days of treatment, the lung lesions were significantly improved comparedwith those in the control group(P<0.05). After 3 weeks of treatment, the PaO_2, SpO_2, dyspnea and pulmonary lesions inthe observation group were significantly improved compared with those in the control group(P<0.05). Conclusion: Theefficacy of methylprednisolone and compound sulfamethoxazole in the treatment of moderate and severe hypoxic AIDSpatients with pneumocystis pneumoniae is relatively accurate, effectively improving the level of PaO_2, SpO_2 and respira-tory difficulties, so as to improve the in whole.
Objective: To evaluate the clinical efficacy of methylprednisolone combined with compound sulfa-methoxazole in moderate and severe hypoxic AIDS with pneumocystis pneumonia and its influence on arterial partialoxygen pressure(PaO_2) and peripheral oxygen saturation(SpO_2). Methods: 60 cases of AIDS complicated with Pneu-mocystis jeroveci pneumonia from January 2015 to January 2018 in our hospital were selected. Based on their differenttreatment methods, they were divided into two groups: the control group(n=30 cases) and the observation group(n=30 cases). The control group was treated with compound sulfamethoxazole, and the observation group was treated withmethylprednisolone combined with sulfamethoxazole. The efficacies of two treatments were compared in total efficientrate. Results: There was no significant difference in PaO_2, SpO_2, dyspnea and pulmonary lesions between the twogroups before treatment(P>0.05). After 7 days of treatment, the PaO_2, SpO_2 and dyspnea in the observation group wereimproved compared with those in the control group(P<0.05), but there was no significant difference in lung conditionbetween the two groups(P>0.05). After 21 days of treatment, the lung lesions were significantly improved comparedwith those in the control group(P<0.05). After 3 weeks of treatment, the PaO_2, SpO_2, dyspnea and pulmonary lesions inthe observation group were significantly improved compared with those in the control group(P<0.05). Conclusion: Theefficacy of methylprednisolone and compound sulfamethoxazole in the treatment of moderate and severe hypoxic AIDSpatients with pneumocystis pneumoniae is relatively accurate, effectively improving the level of PaO_2, SpO_2 and respira-tory difficulties, so as to improve the in whole.
引文
[1]王凤梅,赵爱阳,金敬顺.肺孢子虫肺炎临床研究进展[J].临床肺科杂志,2014,(7):1315-1317.
[2]李爱新,王莉琳,画伟,等.卡泊芬净联合复方磺胺甲噁唑治疗艾滋病合并中重度肺孢子菌肺炎9例报告[J].北京医学,2015,37(9):892-894.
[3]阴赪宏.肺孢子菌肺炎诊断与治疗[M].北京:中国科学技术出版社,2013:125-129.
[4]李爱新,汪雯,张彤,等.卡泊芬净联合复方磺胺甲噁唑治疗艾滋病合并肺孢子菌肺炎临床观察[J].临床荟萃,2017,32(2):163-166.
[5]马英莲,刘明.艾滋病合并卡氏肺孢子虫肺炎11例诊治分析[J].青海医药杂志,2017,(7):12-14.
[6]陈晔锋,周建英.艾滋病合并肺孢子菌肺炎10例诊治分析[J].中国抗生素杂志,2011,36(8):640-640.
[2]李爱新,王莉琳,画伟,等.卡泊芬净联合复方磺胺甲噁唑治疗艾滋病合并中重度肺孢子菌肺炎9例报告[J].北京医学,2015,37(9):892-894.
[3]阴赪宏.肺孢子菌肺炎诊断与治疗[M].北京:中国科学技术出版社,2013:125-129.
[4]李爱新,汪雯,张彤,等.卡泊芬净联合复方磺胺甲噁唑治疗艾滋病合并肺孢子菌肺炎临床观察[J].临床荟萃,2017,32(2):163-166.
[5]马英莲,刘明.艾滋病合并卡氏肺孢子虫肺炎11例诊治分析[J].青海医药杂志,2017,(7):12-14.
[6]陈晔锋,周建英.艾滋病合并肺孢子菌肺炎10例诊治分析[J].中国抗生素杂志,2011,36(8):640-640.